Table 1.
Characteristics of studies included in the meta-analysis
| Author | Sample size | NS | S | Age (years) [IQR]; (SD) | Males N (%) | DM N (%) | HT N (%) | Stroke N (%) | NOS | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NS | S | NS | S | NS | S | NS | S | NS | S | |||||
| Berrill et al. [13] | 50 | 17 | 33 |
75 (10.9) |
60.2 (21.2)* |
6 (35.3) |
16 (48.5) |
8/16 (50.0) |
9/31 (29.0)** |
12 (70.6) |
15/31 (48.4)* |
NR | 8 | |
| Mendes et al. [14] | 235 | 76 | 159 |
86.9 (6.4) |
86 (6.5) |
48 (63.1) |
54 (33.9)** |
23 (30.3) |
31 (19.5) |
56 (73.7) |
112 (70.4) |
15 (20.3) |
31 (19.6) |
8 |
| Quisi et al. [15] | 349 | 38 | 311 |
69 [60–76] |
55 [4–-61]** |
14 (36.8) |
139 (44.7) |
13 (34.2) |
93 (23.9) |
20 (52.6) |
101 (32.5)* |
2 (5.3) |
5 (1.6) |
7 |
| Rodilla et al. [16] | 12226 | 2630 | 9596 |
79.6 (10.5 |
64.1 (15.7)** |
(61.9) § |
(56.2)** § |
23.2 | 16.6 ** | 70.6 | 45.5** | (14.2)§ | (6.0)** | 8 |
| Cipriani et al. [17] | 109 | 20 | 89 |
86 [77–87] |
69 [57–79] |
10 (50.0) |
60 (71.0) |
6 (30.0) |
21 (24.0) |
16 (80.0) |
52 (58.0) |
5 (25.0) |
12 (14.0) |
7 |
| Knights et al. [18] | 103 | 34 | 69 | 78.9 | 63.8** |
20 (59.0) |
38 (55.0) |
14 (41.0) |
10 (14.0) |
18 (53.0) |
28 (41.0) |
11 (32) |
5 (7)* |
8 |
| Shi et al. [19] | 671 | 62 | 609 |
74 [66–81] |
61 [49–70]** |
35 (56.5) |
287 (67.1)** |
17 (27.4) |
80 (13.1)* |
37 (59.7) |
162 (26.6) |
8 (12.9) |
14 (2.3)** |
7 |
| Rossi et al. [20] | 590 | 334 | 256 |
79.5 [73–84] |
73 [64–80] |
187 (73.0) |
212 (63.5)* |
67 (26.2) |
70 (21.0) |
NR |
8 (2.4) |
13 (5.1) |
7 | |
| Cho et al. [21] | 143 | 36 | 107 |
75.8 (16.8) |
68.5 (17.2) |
20 (55.6) |
68 (63.3) |
9 (25.0) |
41 (38.3) |
16 (44.4) |
63 (58.9) |
NR | 8 | |
| Gomez Antúnez et al. [22] | 746 | 286 | 460 |
79 [74–86] |
75 [66–82] |
274 (86.7) |
365 (79.4) |
72 (25.4) |
119 (26.1) |
125 (75.74) |
298 (65.0) |
NR | 8 | |
| Turgay Yidirim et al.[23] | 139 | 26 | 113 |
71.8 (8.9) |
44.0 (19.2) |
19 (73.1) |
66 (58.4) |
9 (34.6) |
12 (10.6)* |
13 (50.0) |
26 (23.0)* |
NR | 8 | |
| Denegri et al. [24] | 201 | 42 | 159 |
79.9 (10.8) |
65.6 (14.1)** |
59.5 § |
65.4 § |
26.2 § |
16.5 § |
64.3 § |
54.4 § |
NR | 7 | |
NS non-survivors, S survivors, IQR interquartile range, SD standard deviation, DM diabetes mellitus, HT arterial hypertension, NOS Newcastle-Ottawa quality assessment scale. *p < 0.05 between non-survivors and survivors; **p < 0.001 between non-survivors and survivors. §Only percentages reported